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MaBACKGROUND The effectiveness of beta-blockers for preventing cardiac events has been questioned for patients who
have coronary heart disease (CHD) without a prior myocardial infarction (MI).
OBJECTIVES The purpose of this study was to assess the association of beta-blockers with outcomes among patients
with new-onset CHD.
METHODS We studied consecutive patients discharged after the ﬁrst CHD event (acute coronary syndrome or coronary
revascularization) between 2000 and 2008 in an integrated healthcare delivery system who did not use beta-blockers in
the year before entry. We used time-varying Cox regression models to determine the hazard ratio (HR) associated with
beta-blocker treatment and used treatment-by-covariate interaction tests (pint) to determine whether the association
differed for patients with or without a recent MI.
RESULTS A total of 26,793 patients were included, 19,843 of whom initiated beta-blocker treatment within 7 days of
discharge from their initial CHD event. Over an average of 3.7 years of follow-up, 6,968 patients had an MI or died. Use of
beta-blockers was associated with an adjusted HR for mortality of 0.90 (95% conﬁdence limits [CL]: 0.84 to 0.96), and
an adjusted HR for death or MI of 0.92 (CL: 0.87 to 0.97). The association between beta-blockers and outcomes differed
signiﬁcantly between patients with and without a recent MI (HR for death: 0.85 vs. 1.02, pint ¼ 0.007; and HR for death
or MI: 0.87 vs. 1.03, pint ¼ 0.005).
CONCLUSIONS Use of beta-blockers among patients with new-onset CHD was associated with a lower risk of cardiac
events only among patients with a recent MI. (J Am Coll Cardiol 2014;64:247–52) © 2014 by the American College of
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ABBR EV I A T I ON S
AND ACRONYMS
ACE = angiotensin-converting
enzyme
ARB = angiotensin receptor
blocker
CABG = coronary artery bypass
graft surgery
CHD = coronary heart disease
CL = 95% conﬁdence limits
HR = hazard ratio
MI = myocardial infarction
NSTEMI = non–ST-segment
elevation myocardial infarction
PCI = percutaneous coronary
intervention
STEMI = ST-segment elevation
myocardial infarction
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248the results of clinical trials in patients with MI
or heart failure to all patients with CHD.
A recent analysis of the observational data
from the REACH (REduction of Athero-
thrombosis for Continued Health) registry
found no signiﬁcant association of beta-blocker
therapy with major adverse cardiovascular
events among patients with stable CHD (8).
This ﬁnding initiated a vigorous debate about
whether beta-blockers improve prognosis
among patients with CHD. The effectiveness of
beta-blockers as ﬁrst-line therapy for hyper-
tension in reducing cardiovascular events
(9,10) and as cardioprotective agents for
noncardiac surgery (11) also has been called
into question. In light of these recent concerns,
we sought to assess the association of beta-
blocker therapy with major adverse cardiacoutcomes among patients with incident CHD.SEE PAGE 253METHODS
SOURCE OF DATA. We used electronic health records
from Kaiser Permanente Northern California, a large,
integrated healthcare delivery system that provides
care to 3.2 million subjects. The membership is broadly
representative of the local population, apart from
slightly lower representation of the extremes of age
and income. The electronic health records collect
comprehensive data on hospitalizations, outpatient
encounters, laboratory test results, and prescription
medications. Diagnoses are coded according to the In-
ternational Classiﬁcation of Diseases (ICD)-9th version,
and procedures are coded using ICD-9CM codes and
Current Procedural Terminology codes, 4th edition.
STUDY POPULATION. We included all patients age 30
years and older who had an initial diagnosis of CHD
between January 1, 2000, and December 31, 2008,
which we deﬁned as hospitalization for acute MI (non–
ST-segment elevation myocardial infarction [NSTEMI]
ICD-9CM codes 410.7 and 410.9 or ST-segment eleva-
tion myocardial infarction [STEMI] codes 410.0 to
410.6 and 410.8), unstable angina (ICD-9CM 411.1), or
having undergone coronary artery bypass graft (CABG)
or percutaneous coronary intervention (PCI). We
excluded patients with any prior diagnoses of MI, un-
stable angina, or coronary revascularization. We also
excluded patients with a history of chronic lung dis-
ease (ICD-9CM 491.x, 492.x, 493.x, 496, 518.1, 518.2),
which is a relative contraindication to beta-blocker
therapy. We adopted a new user design by excluding
patients who received a prescription for a beta-blockerwithin the year before study entry. Patients were
classiﬁed according to their initial presentation as
having had a recent MI, deﬁned as an index hospitali-
zation for either STEMI or NSTEMI.
DEFINITION OF COMORBIDITY, PHARMACOLOGICAL
TREATMENT, AND PATIENT-RELATED CHARACTERISTICS.
We deﬁned comorbid conditions on the basis of in-
hospital and outpatient diagnosis codes in the year
before the incident CHD event. Unless otherwise
described, comorbidities were considered present if at
least 1 prior diagnosis was available in the electronic
health records. A diagnosis of heart failure required at
least 2 outpatient visits with an ICD-9CM code for heart
failure or an inpatient admission with a primary diag-
nosis of heart failure (12). Full codes for classiﬁcation
of the different diseases are available elsewhere (13).
We identiﬁed drug use (beta-blockers, statins,
angiotensin-converting enzyme [ACE] inhibitors,
angiotensin receptor blockers [ARB], and clopidogrel)
on the basis of ﬁlled prescriptions from a Kaiser phar-
macy in the year before the index hospitalization (for
baseline exposure) and during subsequent follow-up.
To account for partial adherence, dose reductions,
and possible persistence of any drug effects after
discontinuation, we considered patients to be on
treatment with a given drug from the date they ﬁlled
the prescription until 30 days after the date when the
prescription would need to be reﬁlled (i.e., allowing a
30-day “grace period”), on the basis of the dosage and
the number of pills dispensed. The grace period is a
conservative assumption in the analysis, as events that
occur within the grace period are then counted as
occurring on-treatment rather than off-treatment.
STUDY START, END, AND DEFINITION OF OUTCOMES.
We followed patients from the index date (7 days af-
ter hospital discharge for their qualifying event) until
December 31, 2008, or disenrollment from the health
plan. We assessed 2 study endpoints: 1) all-cause
mortality, identiﬁed from health plan administrative
databases, Social Security Administration vital status
ﬁles, and the California state death certiﬁcate regis-
try; and 2) the composite of death from any cause or
hospitalization for an acute MI (primary discharge
diagnosis code of 410.x1).
This study was approved by the institutional re-
view boards of the Kaiser Foundation Research In-
stitute and Stanford University.
STATISTICS. We used time-varying multivariable
Cox proportional hazard regression models to assess
the association of beta-blocker use with outcomes,
which allows patients to have on-treatment and
off-treatment periods during follow-up. We used a
series of Cox regression analyses to adjust for
TABLE 1 Baseline Characteristics According to Use of Beta-Blockers
Within 7 Days of Discharge for New-Onset CHD
Overall
(N ¼ 26,793)
Beta-Blockers
(n ¼ 19,843)
No Beta-Blockers
(n ¼ 6,950)
Age, yrs 65.9 64.8 69.2
Male, % 68.3 70.6 61.6
STEMI, % 21.0 23.1 14.9
NSTEMI, % 36.6 37.5 33.9
Unstable angina, % 21.6 20.0 25.9
CABG/PCI, but no ACS, % 20.8 19.3 25.2
Diabetes, % 26.0 25.1 28.5
Heart failure, % 4.8 3.5 8.5
Smoker, % 26.0 27.1 22.8
Liver disease, % 1.0 1.0 0.9
Hypertension, % 41.7 40.5 45.2
Stroke/TIA, % 3.0 2.6 4.2
Atrial ﬁbrillation, % 6.8 5.2 11.1
Major bleeding, % 2.0 1.7 2.8
eGFR >90, % 7.0 7.5 5.6
eGFR 60–89, % 31.8 32.7 29.4
eGFR 45–59, % 15.1 14.4 17.1
eGFR 30–44, % 7.4 6.5 10.3
eGFR 15–39, % 2.4 2.0 3.6
eGFR <15, % 0.4 0.4 0.5
Dialysis, % 1.0 0.8 1.5
Values are %. Baseline characteristics of patients with new-onset CHD who started taking oral
beta-blockers within 7 days of hospital discharge compared with patients who did not initiate
beta-blockers within 7 days.
ACS ¼ acute coronary syndrome; CABG ¼ coronary artery bypass grafting; CHD ¼ coronary
heart disease; eGFR ¼ estimated glomerular ﬁltration rate; NSTEMI ¼ non–ST-segment elevation
myocardial infarction; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation
myocardial infarction; TIA ¼ transient ischemic attack.
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249successively more potential confounding factors. In
the ﬁrst model, we adjusted for baseline demographic
factors, baseline clinical characteristics, and time-
updated indicators of other cardiac drug treatments
(statins, ACE/ARBs, and clopidogrel). In the second
model, we added time-updated indicators of cardiac
procedures (CABG, PCI) and adverse events (heart
failure, unstable angina) in follow-up.
A priori, we speciﬁed the hypothesis that the pres-
ence of a recent MI would modify the association of
beta-blocker use with outcomes. We tested this hy-
pothesis using the probability value for the treatment-
by-covariate interaction test (pint) in the models that
controlled for time-varying beta-blocker exposure
and recent MI, as well as for other baseline covariates
and time-varying exposure to other cardiac drugs.
All analyses were performed with the R statisti-
cal package, version 2.12.2 (R Development Team,
Vienna, Austria).
RESULTS
A total of 64,595 patients were hospitalized for an
initial episode of CHD during the study period, and
28,785 were excluded for prior use of beta-blockers,
7,431 for a history of chronic lung disease, and 1,586
died or had a nonfatal MI before the index date (i.e.,
during the hospital admission or within 7 days after
discharge). Of the 26,793 remaining patients, 19,843
(74%) initiated beta-blocker treatment before the in-
dex date, another 3,819 patients (14%) started beta-
blockers during the subsequent year of follow-up,
and 3,131 patients (12%) did not use beta-blockers
during the average 3.7 years of follow-up. Patients
who initiated beta-blockers within 7 days of discharge
were younger, more likely to be male, and to have
presented with a STEMI, but less likely to have dia-
betes, hypertension, heart failure, or atrial ﬁbrillation
than the remaining patient group (Table 1).
Most patients who initiated treatment with beta-
blocker therapy subsequently had periods off-
treatment, or discontinued beta-blockers entirely:
75% of patients who initiated beta-blockers with-
in 7 days had a gap in treatment during follow-up, with
a mean exposure of 2.5 person-years on-treatment
and 1.1 person-years off-treatment. Of the patients
who later initiated beta-blocker therapy, 77% subse-
quently had a gap in treatment, with 2.4 person-years
on-treatment and 1.2 person-years off-treatment.
Among all study patients, we observed 61,002 person-
years of follow-up on beta-blocker treatment and
36,857 person-years off beta-blocker treatment.
During follow-up, 4,240 patients died and 6,968 had
a cardiac event (death or MI). The crude, unadjustedmortality rate during periods when patients were on
beta-blockers was lower than during periods when
patients were off beta-blockers: 3.6 versus 5.6 per 100
person-years (Table 2). Similarly, the crude, unad-
justed rate of death or MI when patients were taking
beta-blockers was lower than the rate when patients
were not taking beta-blockers: 6.4 versus 8.3 per 100
person-years (Table 2). After adjustment for baseline
factors and time-varying exposure to other cardiac
prescription drugs, beta-blocker treatment was asso-
ciated with a hazard ratio (HR) for death of 0.90 (95%
conﬁdence limit [CL]: 0.84 to 0.96) in the overall
population (Central Illustration). Additional adjust-
ment for the occurrence of coronary revascularization,
unstable angina, and heart failure during follow-up
had relatively little effect on the association of beta-
blockers with mortality, yielding an HR of 0.87 (CL:
0.82 to 0.93).
The use of beta-blockers also was associated
with a signiﬁcantly lower rate of death or MI (Central
Illustration). The HR was 0.92 (CL: 0.87 to 0.97) after
adjustment for baseline characteristics and time-
varying exposure to other cardiac drugs (Central
Illustration), and 0.90 (CL: 0.85 to 0.95) after
TABLE 2 Cardiac Events by Use of Beta-Blockers
Cardiac Event Off Beta-Blockers On Beta-Blockers
All-cause mortality
Total events 2,062 2,178
Years of follow-up 36,847 61,011
Event rate (per 100 person-years) 5.6 3.6
Death or MI
Total events 3,063 3,905
Years of follow-up 36,847 61,011
Event rate (per 100 person-years) 8.3 6.4
Number and rate of cardiac events during periods when patients were on beta-blocker therapy
compared with periods when patients were off beta-blocker therapy. Note that an individual
patient may have periods on and off therapy, depending on the timing of prescription reﬁlls.
MI ¼ myocardial infarction.
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250additional adjustment for cardiac events and pro-
cedures in follow-up.
TREATMENT EFFECT MODIFICATION. We tested the
hypothesis that the association of beta-blocker use
with outcomes would differ among patients with
and without a recent MI. The test for interaction
between beta-blocker treatment and the presence of
recent MI was signiﬁcant both for all-cause mortality
(HR, 0.85; CL: 0.79 to 0.92 vs. HR, 1.02; CL: 0.91 to
1.15; pint ¼ 0.007), as well as for the composite
endpoint of death or MI (HR, 0.87; CL: 0.82 to 0.93
vs. HR, 1.03; CL: 0.93 to 1.13; pint ¼ 0.005).
DISCUSSION
We found that beta-blocker use was associated with
lower overall rates of death or MI in a large, con-
temporary cohort of patients with newly diagnosed
CHD. However, these associations appeared to be
modiﬁed signiﬁcantly by the presence of a recent MI:
there was a strong association of beta-blocker use
with lower cardiac event rates only among patients
who presented with an MI (Central Illustration). Our
ﬁndings are in broad agreement with a recent obser-
vational study from the REACH registry, which also
found no signiﬁcant association of beta-blockers with
cardiac events among patients with stable CHD. The
associations we found between beta-blockers and
reduced cardiac events among patients with a recent
MI also are concordant with the results of previous
randomized trials (1,3,4), which support the validity
of our observational comparisons. These results,
as well as those of prior studies, suggest that
beta-blockers may not reduce adverse cardiac events
in patients who do not have a history of an MI.
Beta-blockers reduce heart rate and have a negative
inotropic effect, thereby reducing myocardial oxygen
demand and ameliorating myocardial ischemia. The
efﬁcacy of beta-blockers in reducing angina andobjective evidence of myocardial ischemia has been
demonstrated in randomized trials that required rela-
tively small sample sizes and relatively short follow-
up of a few weeks (14,15). Because of their salutary
effect on symptoms, beta-blockers became a corner-
stone of medical management of angina. Subse-
quently, clinical trials with larger sample sizes showed
that beta-blockers reduced hard cardiac events among
patients with a recent MI (16), and additional trials
demonstrated the effectiveness of beta-blocker treat-
ment for patients with heart failure and reduced left
ventricular function (17). Clinical guidelines have
therefore given Class I indications to beta-blocker use
for patients after an MI and for patients with heart
failure with reduced systolic function (18).
Although beta-blockers are effective in reducing
anginal symptoms among patients with CHD, there is
scant evidence that they reduce cardiac events among
patients who have neither a recent MI nor heart failure
with systolic dysfunction. Despite a general belief that
beta-blockers may reduce cardiac events in these
lower-risk patients, this indication for use of beta-
blockers only has a Class IIB recommendation, on the
basis of “Level C” evidence—expert opinion only (18).
In fact, several lines of evidence suggest there may be
no effect of beta-blockers on hard outcomes for all
patients with CHD. Our study, and that of the REACH
investigators (8), showed the association of beta-
blocker treatment with outcomes to be signiﬁcantly
stronger in the presence of a recent MI. Similarly, a
recent Japanese observational study of patients with
STEMI also found that the long-term beneﬁcial effect
of beta-blockers was limited to patients who were at a
high baseline risk of adverse outcomes after discharge
(19). Additional evidence comes from recent studies of
noncardiac surgery, which have consistently shown
that the protective effect of beta-blocker therapy is
limited to patients at high risk of cardiovascular
adverse events (20,21). Finally, several hypertension
trials have failed to show any greater effectiveness of
beta-blockers on cardiac events than other classes of
antihypertensive agents (9,10).
There are several possible mechanisms for a
difference in the effectiveness of beta-blockers on the
basis of the presence of a prior MI. Patients with
myocardial damage from an MI have activation of the
sympathetic nervous system, and beta-blockers may
be more effective in such patients because of their
higher levels of sympathetic tone and circulating cat-
echolamines. Use of coronary revascularization in pa-
tients with CHD would be expected to reduce episodes
of myocardial ischemia, which would thereby reduce
any potential beneﬁts of beta-blockers on the basis of
their anti-ischemic properties. This mechanism may
CENTRAL ILLUSTRATION Beta-Blocker Use and Events
(A) Association of beta-blocker use with cardiac events, overall and according
to presence or absence of a prior myocardial infarction (MI). (B) Implications
of study ﬁndings. CAD ¼ coronary artery disease; CL ¼ conﬁdence limits;
HR ¼ hazard ratio.
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251explain why metoprolol had no greater effect than
placebo in reducing mortality during the acute phase
ofMI in the COMMIT (Clopidogrel andMetoprolol inMI
Trial) (22). Finally, patients with CHD who have never
had an MI are at relatively lower risk, and there may be
little room for further risk reduction in the presence of
concomitant guideline-based therapy with statins,
antiplatelet agents, and ACE/ARBs. In this study, we
found a substantial attenuation of the association of
beta-blockers with outcomes after statistical adjust-
ment for the time-varying use of these other cardiac
medications (Central Illustration).
The present study differs from prior studies in
several ways.We adopted a “new user design” to avoid
biases that arise from studying patients on long-term
drug therapy. We also analyzed the data on the basis
of time-varying exposure to beta-blockers, so the same
patient could contribute to the analyses as being “on
beta-blockers” for some intervals and “off beta-
blockers” for other periods. This approach differs from
the intention-to-treat framework used in randomized
trials, in which patients originally assigned to a ther-
apy are assumed to be on that therapy throughout
follow-up, regardless of whether they are adherent or
cross over to alternative treatments. The time-varying
analysis method should yield greater risk reductions
for treatment with an effective drug, as the intention-
to-treat estimate is diluted by periods of non-
adherence, whereas the time-varying estimate of
effect is not. However, patients who are adherent
with drug treatment tend to have more favorable
clinical characteristics, which may bias estimates of
treatment effectiveness. In this study, we found that
adjustment for time-varying use of statins, ACE/ARBs,
and clopidogrel attenuated the association of (time-
varying) exposure to beta-blockers with mortality. We
believe that controlling for time-varying exposures to
all cardiac medications is therefore the best approach,
as it also controls for patient factors related to overall
adherence with prescribed therapies.
STUDY LIMITATIONS. Although we had information
on a wide variety of clinical variables, the datasets did
not include information on several factors, such as the
extent of coronary artery disease, left ventricular
ejection fraction, and patient’s functional capacity.
Furthermore, we do not have any information onwhy a
patient was on or off beta-blockers at any particular
time. Patients may have discontinued their use of
beta-blocker treatment because of side effects, such
as fatigue, bradycardia, hypotension, depression, or
sexual dysfunction, which may identify higher-risk
patients. Furthermore, because this study was obser-
vational, we cannot exclude residual confounding
that might have affected our estimates of treatmenteffectiveness. Use of time-dependent Coxmodels are a
form of “on-treatment” analysis in which medications
can appear to be more effective because a claimed
prescription is associated with compliance and
perhaps a “healthy user effect.” Despite these poten-
tial biases, we found no signiﬁcant association of beta-
blockers with outcomes among patients without a
recent MI.
CONCLUSIONS
Among patients with newly diagnosed CHD, beta-
blockers were associated with a lowered rate of car-
diac events only among patients at higher risk
because of a recent MI. A randomized clinical trial is
warranted to test whether beta-blockers reduce the
risk of hard endpoints among lower-risk patients who
have CHD, but have not had an MI.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Both
randomized trials and observational studies have shown
that beta-blockers reduce mortality and reinfarction in
patients with recent MI, but other studies suggest that
beta-blockers may not prevent cardiac events in patients
with CHD who have not sustained recent MI.
COMPETENCY IN SYSTEMS-BASED PRACTICE:
Clinical practice guidelines recommend beta-blockers for
survivors of recent MI (Class I), and that this form of
therapy be considered for patients with coronary disease
who have not sustained recent MI (Class IIB).
TRANSLATIONAL OUTLOOK: Randomized trials are
needed to assess the safety, efﬁcacy, and net clinical
beneﬁt of beta-blockers among patients with coronary
disease who have not had recent MI.
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